HDAC6 regulates human erythroid differentiation through modulation of JAK2 signalling.

Among histone deacetylases, HDAC6 is unusual in its cytoplasmic localization. Its inhibition leads to hyperacetylation of non-histone proteins, inhibiting cell cycle, proliferation and apoptosis. Ricolinostat (ACY-1215) is a selective inhibitor of the histone deacetylase HDAC6 with proven efficacy in the treatment of malignant diseases, but anaemia is one of the most frequent side effects. We investigated here the underlying mechanisms of this erythroid toxicity. We first confirmed that HDAC6 was strongly expressed at both RNA and protein levels in CD34+ -cells-derived erythroid progenitors. ACY-1215 exposure on CD34+ -cells driven in vitro towards the erythroid lineage led to a decreased cell count, an increased apoptotic rate and a delayed erythroid differentiation with accumulation of weakly hemoglobinized immature erythroblasts. This was accompanied by drastic changes in the transcriptomic profile of primary cells as shown by RNAseq. In erythroid cells, ACY-1215 and shRNA-mediated HDAC6 knockdown inhibited the EPO-dependent JAK2 phosphorylation. Using acetylome, we identified 14-3-3ζ, known to interact directly with the JAK2 negative regulator LNK, as a potential HDAC6 target in erythroid cells. We confirmed that 14-3-3ζ was hyperacetylated after ACY-1215 exposure, which decreased the 14-3-3ζ/LNK interaction while increased LNK ability to interact with JAK2. Thus, in addition to its previously described role in the enucleation of mouse fetal liver erythroblasts, we identified here a new mechanism of HDAC6-dependent control of erythropoiesis through 14-3-3ζ acetylation level, LNK availability and finally JAK2 activation in response to EPO, which is crucial downstream of EPO-R activation for human erythroid cell survival, proliferation and differentiation.

Low UVA doses activate the transcription factor NFAT in human fibroblasts by a calcium-calcineurin pathway.

UVA radiation induces an inflammatory response as observed in erythema, and the cytokine genes involved in this response are under the control of the transcription factor NFAT (nuclear factor of activated T lymphocytes). The effects of UVA on NFAT DNA binding activity were investigated in cultured human fibroblasts. A dose-dependent increase was observed within the range of 0.6-4.5 J/cm2 UVA. Beyond this value, the activity decreased and a value of 60% of control was found at 13.5 J/cm2. The enhancement of NFAT activity was transient and peaked 45 min after irradiation. Furthermore, immunoblot analysis demonstrated a nuclear translocation of NFAT under low UVA doses. Concomitantly, as assessed by the fluorescent probe Fluo3, UVA induced an increase in intracellular free calcium, with a maximum increase found at 9 J/cm2. The UVA-induced activation of NFAT was prevented by the intracellular calcium trapping drug BAPTA, whereas the extracellular calcium chelator EGTA had no significant effect. In addition, the calcineurin inhibitors cyclosporin A and FK506 both prevented the UVA-induced NFAT activation. Furthermore, the antioxidant vitamin E prevented the UVA-induced increase in both intracellular free calcium and NFAT binding activity. Finally, the cytotoxicity of UVA was enhanced in the presence of the inhibitors cyclosporin and FK506, suggesting that the activation of NFAT might play a protective role after the UVA-induced oxidative stress. These results demonstrate that UVA activates the calcium-calcineurin signaling pathway of NFAT activation, that the calcium ions are mainly released from intracellular stores, and that the increase in calcium is, at least partially, due to the oxidative stress generated under UVA. Because NFAT regulates several genes implicated in the inflammatory response, the enhancement of NFAT activity by low UVA doses might be interpreted in view of the proinflammatory action of solar radiation.